Laverock Therapeutics

A Stevenage gene-silencing company developing programmable cell and gene treatments, using the body's own microRNAs.

About Laverock Therapeutics

Laverock Therapeutics works on programmable treatments that switch off chosen genes in a controlled way. Its platform redirects microRNAs, small molecules the body already makes, so that cells can be programmed. It is focused on cancer and genetic diseases, including Charcot-Marie-Tooth disease.

Its chief executive David Venables said Laverock is "uniquely positioned to generate powerful and entirely novel advanced therapies" (company's own words, September 2024). We did not find a longer mission statement.

Laverock is based at Stevenage Bioscience Catalyst in Stevenage, Hertfordshire, a hub for life-science start-ups. It has also won an Innovate UK award for its immune cell therapy work (October 2023).

Its release says it has a highly experienced leadership team and board, but names only the chief executive. We found no culture details.

We found no information on graduate schemes, internships or apprenticeships. Stevenage has a large cluster of cell and gene therapy employers, so it is a good area to look for entry roles and work experience.

What they do

• {'desc': 'Uses microRNAs to switch genes off in a controlled way.', 'title': 'Programmable gene silencing'}
• {'desc': 'Pipeline in oncology and genetic disease.', 'title': 'Cell and gene therapy'}
• {'desc': 'Seeks partners for diabetes, inflammation and fibrosis.', 'title': 'Partnering'}

Key facts

• Based at Stevenage Bioscience Catalyst (September 2024 release)
• Chief executive David Venables
• Won an Innovate UK award, October 2023 (BioIT World report)
• Pipeline includes Charcot-Marie-Tooth disease

Website: www.laverocktx.com